Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway

Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective hypoglycemic drug; however, the effects of empagliflozin on hepatic g...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaochen, Meng, Ziyu, Fang, Ting, Liu, Xiaohuan, Cheng, Ying, Xu, Linxin, Liu, Xiangyang, Li, Xiaoyu, Xue, Mei, Li, Ting, Sun, Bei, Chen, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921641/
https://www.ncbi.nlm.nih.gov/pubmed/35299662
http://dx.doi.org/10.3389/fphys.2022.817542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921641/
https://www.ncbi.nlm.nih.gov/pubmed/35299662
http://dx.doi.org/10.3389/fphys.2022.817542

Ejemplares similares